Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

Study Overview
=================
Brief Summary
-----------------
This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of NAFLD and/or NASH. The study will be conducted over a period of up to 22 weeks and will include an optional Prescreening, Screening (Days -35 to -7) Phase, a 16-week Treatment Phase following randomization on Day 1. Patients will be randomly assigned in a ratio of 1:1:1:1 to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks. The primary endpoint of the study is percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group.

Official Title
-----------------
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

Conditions
-----------------
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis

Intervention / Treatment
-----------------
* Drug: Saroglitazar magnesium 1 mg
* Drug: Saroglitazar magnesium 2 mg
* Drug: Saroglitazar magnesium 4 mg
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females, 18 to 75 years of age, with body mass index (BMI) ≥ 25 kg/m2. Documented diagnosis of NAFLD established either by imaging (ultrasound, CT scan or MRI) or liver biopsy showing NASH or simple steatosis, within the 24 months preceding Visit 1. The diagnosis of NAFLD is made according to the American Association for the Study of Liver Diseases (AASLD) criteria (Chalasani et al. Hepatology 2012; 55:2005-2023). ALT level of ≥50 U/L at Visit 1 and Visit 2 with ≤30% variance between the levels at Visit 1 and Visit 2. Patient's demonstration of understanding of study requirements and treatment procedures, willingness to comply with all protocol-required evaluations; provision of written informed consent before any study specific tests or procedures are performed. Exclusion Criteria: Consumption of > 3 units of alcohol per day (> 21 units per week) if male and > 2 units of alcohol per day (>14 units per week) if female for at least 3 consecutive months in the 5 years preceding Visit 1 (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor). Presence of alternative causes of fatty liver, including: Weight change >5% within the 3 months preceding Visit 1 Total parenteral nutrition, starvation or protein-calorie malnutrition within the 90 days preceding Visit 1. Use of drugs associated with NAFLD for more than 12 consecutive weeks in the 1 year before Visit 1, including amiodarone, tamoxifen, methotrexate, systemic glucocorticoids, anabolic steroids, tetracycline, estrogens in doses higher than used in oral contraceptives, vitamin A, L asparaginase, valproate, chloroquine or antiretroviral drugs Initiation of vitamin E at doses > 100 IU/day, or multivitamins containing > 100 IU/day of vitamin E in the 3 months preceding Visit 1. Use of drugs with potential effect on NASH such as ursodeoxycholic acid, S-adenosylmethionine (SAM-e), betaine, pentoxifylline, obeticholic acid or milk thistle in the 3 months prior to Visit 1. Changing doses of statins (simvastatin, pitavastatin, pravastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin) or fibrates (clofibrate, fenofibrate) in the 3 months preceding Visit 1. Use of thiazolidinediones (pioglitazone, rosiglitazone). Use of drugs that are known CYP2C8 inhibitors/substrate History of bowel surgery (gastrointestinal (bariatric) surgery or undergoing evaluation for bariatric surgery for obesity, extensive small-bowel resection or orthotopic liver transplant (OLT) or listed for OLT. History of other chronic liver disease (chronic hepatitis C, (HCV) infection, irrespective of their mRNA HCV assay status or active hepatitis B infection, (i.e., serum positive for hepatitis B surface antigen) or autoimmune hepatitis, cholestatic and metabolic liver diseases) or hemochromatosis Patient has known cirrhosis, either based on clinical criteria or liver histology. Patient with INR >1.3. Type 1 diabetes mellitus. Poorly controlled type 2 diabetes mellitus, i.e., glycosylated hemoglobin (HbA1c) > 9%. Unstable cardiovascular disease, including: unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the 3 months preceding Visit 1), acute coronary syndrome within the 6 months preceding Visit 1, acute myocardial infarction within the 3 months preceding Visit 1 or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the 6 months preceding Visit 1 history of (within 3 months preceding Visit 1) or current unstable cardiac dysrhythmias uncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg and/or diastolic BP > 100 mmHg) stroke or transient ischemic attack within the 6 months preceding Visit 1. History of myopathies or evidence of active muscle disease. History of malignancy in the 5 years preceding Visit 1 and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer. Any of the following laboratory values: Hemoglobin < 9 g/dL White blood cell count < 2.5 × 103/μL Neutrophil count < 1.5 × 103/μL Platelets < 100 × 103/μL Total Serum bilirubin > 1.5 mg/dL (except in patient with known Gilbert bilirubin where TB up to 2.5 mg/dL is allowed), if it is <1.5 mg/dL at screening and >30% variance in the levels at Visit 1 and Visit 2 Albumin < 3.2 g/dL Serum creatinine >1.5 mg/dL Serum ALT or AST > 250 IU/L at Visit 1 or Visit 2 . Contraindications to Saroglitazar Magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar Magnesium. Known allergy, sensitivity or intolerance to the study drug, placebo or formulation ingredients. Participation in any other therapeutic clinical study within the 3 months preceding Visit 1, including participation in any other NAFLD/NASH clinical trials. History of bladder disease and/or hematuria or has current hematuria except due to a urinary tract infection. Illicit substance abuse within the 12 months preceding Visit 1. Pregnancy-related exclusions, including: Pregnant/lactating female (including a positive serum pregnancy test at Visit 1) A male patient has to use a condom with spermicide, and the female partner of the male patient has to use an intrauterine device OR a diaphragm with spermicide OR oral contraceptive pills. If a male patient has undergone a vasectomy, the female partner does not have to use any contraception. A female patient has to use either an intrauterine device OR a diaphragm with spermicide OR oral contraceptive pills. The male partner of the female patient has to use a condom with spermicide. If the female patient is surgically sterilized for at least the 6 months preceding Visit 1 or postmenopausal, defined as at least 12 months with no menses and without an alternative cause, the male partner of the female patient does not have to use any contraception. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, HIV, coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Saroglitazar magnesium 1 mg<br>Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks. | Drug: Saroglitazar magnesium 1 mg<br>* Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.<br>|
| Experimental: Saroglitazar magnesium 2 mg<br>Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks. | Drug: Saroglitazar magnesium 2 mg<br>* Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.<br>|
| Experimental: Saroglitazar magnesium 4 mg<br>Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks. | Drug: Saroglitazar magnesium 4 mg<br>* Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.<br>|
| Placebo Comparator: Placebos<br>Placebo tablet orally once daily in the morning before breakfast for 16 weeks. | Drug: Placebos<br>* Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage change from baseline in serum ALT levels at Week 16 | Percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group | 16 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in liver fat content as measured by magnetic resonance imaging-derived proton density-fat fraction (MRI-PDFF) | Change in liver fat content as measured by magnetic resonance imaging-derived proton in Saroglitazar Magnesium groups as compared to the placebo group | 16 Weeks | 
| Proportion of patients with sustain decrease in serum ALT levels | Proportion of patients with sustain decrease in serum ALT levels in Saroglitazar Magnesium groups as compared to the placebo group | 16 Weeks | 
| Changes in cytokeratin-18 | Changes in cytokeratin-18 in Saroglitazar Magnesium groups as compared to the placebo group | 16 Weeks | 
| Changes in enhanced liver fibrosis | Changes in enhanced liver fibrosis in Saroglitazar Magnesium groups as compared to the placebo group | 16 Weeks | 
| Change in aspartate aminotransferase-to-platelet ratio index | Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group | 16 Weeks | 
| Pharmacokinetics of Saroglitazar Magnesium: maximum plasma concentration (Cmax) | Maximum plasma concentration (Cmax) of Saroglitazar | 16 Weeks | 
| Time to reach maximum plasma concentration (Tmax) | Time to reach maximum plasma concentration (Tmax) of saroglitazar | 16 Week | 
| Terminal half life (t1/2) | Terminal half life (t1/2) of saroglitazar | 16 Weeks | 
| Area under the curve from the time of dosing to the last measurable concentration (AUC0-t) | Area under the curve from the time of dosing to the last measurable concentration for saroglitazar | 16 Week | 
| Area under the curve from the time of dosing to the infinity (AUC 0-inf) | Area under the curve from the time of dosing to the infinity (AUC 0-inf) for Saroglitazar | 16 Week | 
| Elimination rate constant (λz) | Elimination rate constant (λz) for saroglitazar | 16 Week | 
| Apparent volume of distribution (Vd/F) | Apparent volume of distribution (Vd/F) for Saroglitazar | 16 Week | 
| Apparent clearance (CL/F) | Apparent clearance (CL/F) for Saroglitazar | 16 Week | 
| Change in quality of life assessed by the Short-Form 36 Health Survey | Quality of life will be assessed by the Short-Form 36 Health Survey | 16 Week | 
| Safety and tolerability of Saroglitazar Magnesium | Assessed by incidence of adverse events | 16 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NAFLD, NASH, Saroglitazar